UNIGE document Scientific Article
previous document  unige:110027  next document
add to browser collection
Title

Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits

Authors
Perrotta, Gaetano
Bonnier, Guillaume
Meskaldji, Djalel-Eddine
Romascano, David
Aydarkhanov, Ruslan
Daducci, Alessandro
Simioni, Samanta
Cavassini, Matthias
show hidden authors show all authors [1 - 14]
Published in Annals of Clinical and Translational Neurology. 2017, vol. 4, no. 12, p. 915-920
Abstract Rivastigmine has been shown to improve cognition in HIV+ patients with minor neurocognitive disorders; however, the mechanisms underlying such beneficial effect are currently unknown. To assess whether rivastigmine therapy is associated with decreased brain inflammation and damage, we performed T1/T2* relaxometry and magnetization transfer imaging in 17 aviremic HIV+ patients with minor neurocognitive disorders enrolled on a crossed over randomized rivastigmine trial. Rivastigmine therapy was associated with changes in MRI metrics indicating a decrease in brain water content (i.e., edema reabsorption) and/or reduced demyelination/axonal damage. Furthermore, MRI changes correlated with cognitive improvement on rivastigmine therapy.
Identifiers
PMID: 29296621
Full text
Article (Published version) (202 Kb) - public document Free access
Structures
Research group Groupe Lazeyras Francois (IRM fonctionnelle et métabolique) (539)
Citation
(ISO format)
PERROTTA, Gaetano et al. Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits. In: Annals of Clinical and Translational Neurology, 2017, vol. 4, n° 12, p. 915-920. doi: 10.1002/acn3.493 https://archive-ouverte.unige.ch/unige:110027

165 hits

79 downloads

Update

Deposited on : 2018-10-30

Export document
Format :
Citation style :